Eli Lilly strikes deal to sell obesity drugs directly on Hims & Hers platform
Eli Lilly announced a partnership allowing Hims & Hers Health to sell its obesity drugs Zepbound and Foundayo directly on the telehealth platform, sending Hims & Hers shares up more than 7%. The deal marks a significant course change for Hims, which had previously sold compounded GLP-1 knockoffs.
